Skip to main content
PMC home page
Antimicrobial Agents and Chemotherapy logoLink to Antimicrobial Agents and Chemotherapy
. 1995 May;39(5):1050–1053. doi: 10.1128/aac.39.5.1050

Effect of fluconazole on pharmacokinetics of 2',3'-dideoxyinosine in persons seropositive for human immunodeficiency virus.

V L Bruzzese 1, J G Gillum 1, D S Israel 1, G L Johnson 1, L G Kaplowitz 1, R E Polk 1
PMCID: PMC162681  PMID: 7625787

Abstract

Fluconazole inhibits cytochrome P-450-mediated enzymatic metabolism of several drugs. Since hepatic metabolism is partially responsible for 2',3'-dideoxyinosine (didanosine or ddI) elimination, fluconazole therapy may lead to increased ddI concentrations in serum and subsequent concentration-dependent adverse effects. The purpose of this study was to determine if ddI pharmacokinetics are influenced by a 7-day course of oral fluconazole. Twelve adults with human immunodeficiency virus (HIV) who had received a constant dosage of ddI for at least 2 weeks were investigated. On study day 1, multiple serum samples for determination of ddI concentrations were obtained over 12 h. Then subjects received a 7-day course of oral fluconazole (200 mg every 12 h for two doses and then 200 mg once daily for 6 days) while ddI therapy continued. Following the last dose of fluconazole, serum samples for determination of ddI concentrations were again obtained over 12 h. ddI concentrations in serum were analyzed by radioimmunoassay. In contrast to previously published data, there was marked between-subject variability in ddI areas under the concentration-time curve, even when the dose was normalized for weight. No significant differences were found between mean ddI areas under the concentration-time curve from 0 to 12 h on study day 1 (1,528 +/- 902 ngx.hr/ml) and following fluconazole treatment (1,486 +/- 649 ngx.hr/ml) .There were no significant differences in other pharmacokinetic parameters, such as ddI peak concentrations in serum (971 +/- 509 and 942 +/- 442 ng/ml) or half-lives (80 +/- 32 and 85 +/- 21 min.) before and after fluconazole treatment, respectively. We conclude that a 7-day course of oral fluconazole does not significantly alter ddI pharmacokinetics in adults that are infected with human immunodeficiency virus.

Full Text

The Full Text of this article is available as a PDF (181.6 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Abrams D. I., Goldman A. I., Launer C., Korvick J. A., Neaton J. D., Crane L. R., Grodesky M., Wakefield S., Muth K., Kornegay S. A comparative trial of didanosine or zalcitabine after treatment with zidovudine in patients with human immunodeficiency virus infection. The Terry Beirn Community Programs for Clinical Research on AIDS. N Engl J Med. 1994 Mar 10;330(10):657–662. doi: 10.1056/NEJM199403103301001. [DOI] [PubMed] [Google Scholar]
  2. Back D. J., Ormesher S., Tjia J. F., Macleod R. Metabolism of 2',3'-dideoxyinosine (ddI) in human blood. Br J Clin Pharmacol. 1992 Mar;33(3):319–322. doi: 10.1111/j.1365-2125.1992.tb04043.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Connolly K. J., Allan J. D., Fitch H., Jackson-Pope L., McLaren C., Canetta R., Groopman J. E. Phase I study of 2'-3'-dideoxyinosine administered orally twice daily to patients with AIDS or AIDS-related complex and hematologic intolerance to zidovudine. Am J Med. 1991 Nov;91(5):471–478. doi: 10.1016/0002-9343(91)90182-w. [DOI] [PubMed] [Google Scholar]
  4. Cooley T. P., Kunches L. M., Saunders C. A., Ritter J. K., Perkins C. J., McLaren C., McCaffrey R. P., Liebman H. A. Once-daily administration of 2',3'-dideoxyinosine (ddI) in patients with the acquired immunodeficiency syndrome or AIDS-related complex. Results of a Phase I trial. N Engl J Med. 1990 May 10;322(19):1340–1345. doi: 10.1056/NEJM199005103221902. [DOI] [PubMed] [Google Scholar]
  5. DeMuria D., Forrest A., Rich J., Scavone J. M., Cohen L. G., Kazanjian P. H. Pharmacokinetics and bioavailability of fluconazole in patients with AIDS. Antimicrob Agents Chemother. 1993 Oct;37(10):2187–2192. doi: 10.1128/aac.37.10.2187. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Drusano G. L., Yuen G. J., Lambert J. S., Seidlin M., Dolin R., Valentine F. T. Relationship between dideoxyinosine exposure, CD4 counts, and p24 antigen levels in human immunodeficiency virus infection. A phase I trial. Ann Intern Med. 1992 Apr 1;116(7):562–566. doi: 10.7326/0003-4819-116-7-562. [DOI] [PubMed] [Google Scholar]
  7. Drusano G. L., Yuen G. J., Morse G., Cooley T. P., Seidlin M., Lambert J. S., Liebman H. A., Valentine F. T., Dolin R. Impact of bioavailability on determination of the maximal tolerated dose of 2',3'-dideoxyinosine in phase I trials. Antimicrob Agents Chemother. 1992 Jun;36(6):1280–1283. doi: 10.1128/aac.36.6.1280. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Gillum J. G., Israel D. S., Polk R. E. Pharmacokinetic drug interactions with antimicrobial agents. Clin Pharmacokinet. 1993 Dec;25(6):450–482. doi: 10.2165/00003088-199325060-00005. [DOI] [PubMed] [Google Scholar]
  9. Katzenstein D. A., Winters M., Bubp J., Israelski D., Winger E., Merigan T. C. Quantitation of human immunodeficiency virus by culture and polymerase chain reaction in response to didanosine after long-term therapy with zidovudine. J Infect Dis. 1994 Feb;169(2):416–419. doi: 10.1093/infdis/169.2.416. [DOI] [PubMed] [Google Scholar]
  10. Kaul S., Shyu W. C., Shukla U. A., Dandekar K. A., Barbhaiya R. H. Absorption, disposition, and metabolism of [14C]didanosine in the beagle dog. Drug Metab Dispos. 1993 May-Jun;21(3):447–453. [PubMed] [Google Scholar]
  11. Knupp C. A., Brater D. C., Relue J., Barbhaiya R. H. Pharmacokinetics of didanosine and ketoconazole after coadministration to patients seropositive for the human immunodeficiency virus. J Clin Pharmacol. 1993 Oct;33(10):912–917. doi: 10.1002/j.1552-4604.1993.tb01921.x. [DOI] [PubMed] [Google Scholar]
  12. Knupp C. A., Milbrath R. L., Barbhaiya R. H. Effect of metoclopramide and loperamide on the pharmacokinetics of didanosine in HIV seropositive asymptomatic male and female patients. Eur J Clin Pharmacol. 1993;45(5):409–413. doi: 10.1007/BF00315510. [DOI] [PubMed] [Google Scholar]
  13. Knupp C. A., Milbrath R., Barbhaiya R. H. Effect of time of food administration on the bioavailability of didanosine from a chewable tablet formulation. J Clin Pharmacol. 1993 Jun;33(6):568–573. doi: 10.1002/j.1552-4604.1993.tb04705.x. [DOI] [PubMed] [Google Scholar]
  14. Knupp C. A., Shyu W. C., Dolin R., Valentine F. T., McLaren C., Martin R. R., Pittman K. A., Barbhaiya R. H. Pharmacokinetics of didanosine in patients with acquired immunodeficiency syndrome or acquired immunodeficiency syndrome-related complex. Clin Pharmacol Ther. 1991 May;49(5):523–535. doi: 10.1038/clpt.1991.63. [DOI] [PubMed] [Google Scholar]
  15. Lambert J. S., Seidlin M., Reichman R. C., Plank C. S., Laverty M., Morse G. D., Knupp C., McLaren C., Pettinelli C., Valentine F. T. 2',3'-dideoxyinosine (ddI) in patients with the acquired immunodeficiency syndrome or AIDS-related complex. A phase I trial. N Engl J Med. 1990 May 10;322(19):1333–1340. doi: 10.1056/NEJM199005103221901. [DOI] [PubMed] [Google Scholar]
  16. Pai S. M., Shukla U. A., Grasela T. H., Knupp C. A., Dolin R., Valentine F. T., McLaren C., Liebman H. A., Martin R. R., Pittman K. A. Population pharmacokinetic analysis of didanosine (2',3'-dideoxyinosine) plasma concentrations obtained in phase I clinical trials in patients with AIDS or AIDS-related complex. J Clin Pharmacol. 1992 Mar;32(3):242–247. doi: 10.1002/j.1552-4604.1992.tb03832.x. [DOI] [PubMed] [Google Scholar]
  17. Sahai J., Gallicano K., Pakuts A., Cameron D. W. Effect of fluconazole on zidovudine pharmacokinetics in patients infected with human immunodeficiency virus. J Infect Dis. 1994 May;169(5):1103–1107. doi: 10.1093/infdis/169.5.1103. [DOI] [PubMed] [Google Scholar]
  18. Spruance S. L., Pavia A. T., Peterson D., Berry A., Pollard R., Patterson T. F., Frank I., Remick S. C., Thompson M., MacArthur R. D. Didanosine compared with continuation of zidovudine in HIV-infected patients with signs of clinical deterioration while receiving zidovudine. A randomized, double-blind clinical trial. The Bristol-Myers Squibb AI454-010 Study Group. Ann Intern Med. 1994 Mar 1;120(5):360–368. doi: 10.7326/0003-4819-120-5-199403010-00002. [DOI] [PubMed] [Google Scholar]

Articles from Antimicrobial Agents and Chemotherapy are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES